Oral Solution Formulation of Abilify (Aripiprazole) Is Ratified
Abilify antipsychotic medicine was introduced in 2002 as the first and only dopamine partial agonist. It is generally prescribed for the treatment of schizophrenia disease and acute manic and mixed episodes associated with bipolar disorder.
It has been known today that the US Food and Drug Administration (FDA) approved an oral solution formulation of Abilify (aripiprazole). As Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co, Ltd., state, the oral solution formulation will be available in pharmacies in February 2005. Abilify drug Oral Solution is considered to be a new option for adult patients who have difficulty swallowing tablets.
According to the words of Anthony Hooper, president, U.S. Pharmaceuticals, Bristol-Myers Squibb Company, Abilify medication Oral Solution is directed to satisfaction of the special needs of patients and provides effective treatment, helping doctors to manage special patients.
Otsuka Pharmaceutical Co., Ltd. is very proud to have developed Aripiprazole drug. Its president and representative director, Tatsuo Higuchi says that the two approved formulations give flexibility in supporting the management of patients requiring different options. And they are encouraged to have their strong focus on pharmaceutical innovation.
